Literature DB >> 2200126

Toxoplasma gondii: fusion competence of parasitophorous vacuoles in Fc receptor-transfected fibroblasts.

K A Joiner1, S A Fuhrman, H M Miettinen, L H Kasper, I Mellman.   

Abstract

After actively entering its host cells, the protozoan parasite Toxoplasma gondii resides in an intracellular vacuole that is completely unable to fuse with other endocytic or biosynthetic organelles. The fusion blocking requires entry of viable organisms but is irreversible: fusion competence of the vacuole is not restored if the parasite is killed after entry. The fusion block can be overcome, however, by altering the parasite's route of entry. Thus, phagocytosis of viable antibody-coated T. gondii by Chinese hamster ovary cells transfected with macrophage-lymphocyte Fc receptors results in the formation of vacuoles that are capable of both fusion and acidification. Phagocytosis and fusion appear to involve a domain of the Fc receptor cytoplasmic tail distinct from that required for localization at clathrin-coated pits. These results suggest that the mechanism of fusion inhibition is likely to reflect a modification of the vacuole membrane at the time of its formation, as opposed to the secretion of a soluble inhibitor by the parasite.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2200126     DOI: 10.1126/science.2200126

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  140 in total

1.  Toxoplasma gondii myosin A and its light chain: a fast, single-headed, plus-end-directed motor.

Authors:  Angelika Herm-Götz; Stefan Weiss; Rolf Stratmann; Setsuko Fujita-Becker; Christine Ruff; Edgar Meyhöfer; Thierry Soldati; Dietmar J Manstein; Michael A Geeves; Dominique Soldati
Journal:  EMBO J       Date:  2002-05-01       Impact factor: 11.598

Review 2.  Cytoskeleton of apicomplexan parasites.

Authors:  Naomi S Morrissette; L David Sibley
Journal:  Microbiol Mol Biol Rev       Date:  2002-03       Impact factor: 11.056

3.  Opsonization modulates Rac-1 activation during cell entry by Leishmania amazonensis.

Authors:  J Morehead; I Coppens; N W Andrews
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

4.  Mechanism of entry determines the ability of Toxoplasma gondii to inhibit macrophage proinflammatory cytokine production.

Authors:  Barbara A Butcher; Eric Y Denkers
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

5.  Biogenesis of nanotubular network in Toxoplasma parasitophorous vacuole induced by parasite proteins.

Authors:  Corinne Mercier; Jean-François Dubremetz; Béatrice Rauscher; Laurence Lecordier; L David Sibley; Marie-France Cesbron-Delauw
Journal:  Mol Biol Cell       Date:  2002-07       Impact factor: 4.138

6.  Alterations in the protein composition of maturing phagosomes.

Authors:  A Pitt; L S Mayorga; P D Stahl; A L Schwartz
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

7.  Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis.

Authors:  Joanna Rejman; Volker Oberle; Inge S Zuhorn; Dick Hoekstra
Journal:  Biochem J       Date:  2004-01-01       Impact factor: 3.857

8.  Transferrin receptor induction in Toxoplasma gondii-infected HFF is associated with increased iron-responsive protein 1 activity and is mediated by secreted factors.

Authors:  Markus Gail; Uwe Gross; Wolfgang Bohne
Journal:  Parasitol Res       Date:  2004-09-01       Impact factor: 2.289

9.  Dendritic cell activation prevents MHC class II ubiquitination and promotes MHC class II survival regardless of the activation stimulus.

Authors:  Even Walseng; Kazuyuki Furuta; Romina S Goldszmid; Karis A Weih; Alan Sher; Paul A Roche
Journal:  J Biol Chem       Date:  2010-11-03       Impact factor: 5.157

10.  Targeted disruption of the GRA2 locus in Toxoplasma gondii decreases acute virulence in mice.

Authors:  C Mercier; D K Howe; D Mordue; M Lingnau; L D Sibley
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.